Clinical Trial Update: Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib with paclitaxel and carboplatin in stage III/IV or recurrent non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• ERLOTINIB (Erlotinib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-12-06